GPCPD1抗体—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: A549 cell lysate, Primary antibody: P10212(GPCPD1 Antibody) at dilution 1/800, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 50 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P10212(GPCPD1 Antibody) at dilution 1/55. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human prostate cancer tissue using P10212(GPCPD1 Antibody) at dilution 1/55. (Original magnification: ×200)    

  
  

The GPCPD1 (Glycerophosphocholine Phosphodiesterase 1) antibody is a tool used to study the enzyme encoded by the *GPCPD1* gene, which hydrolyzes glycerophosphocholine (GPC) to produce choline and glycerol-3-phosphate. This enzyme plays a role in lipid metabolism and choline recycling, processes critical for maintaining cell membrane integrity and neurotransmission. GPCPD1 is expressed in various tissues, including the liver, brain, and kidney, and its dysregulation has been implicated in metabolic disorders, neurodegenerative diseases, and cancer progression.

Antibodies targeting GPCPD1 are primarily utilized in biomedical research to investigate its expression patterns, subcellular localization, and functional roles. They enable techniques such as Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF) to quantify protein levels or visualize tissue distribution. Recent studies suggest GPCPD1 may influence phosphatidylcholine metabolism, impacting cell proliferation and apoptosis, making it a potential biomarker or therapeutic target in cancers like hepatocellular carcinoma.

Commercial GPCPD1 antibodies are typically raised in rabbits or mice, with validation data including specificity checks via knockout controls. Researchers rely on these reagents to explore GPCPD1's interplay with metabolic pathways and its broader implications in disease mechanisms. However, variability in antibody performance across experimental conditions underscores the need for rigorous validation to ensure reproducibility in studies.